SRPT

Sarepta Therapeutics, Inc.
CAPPED RATING

Sarepta Therapeutics Inc is a biotechnology company. It uses proprietary RNA-targeted technology platforms for developing pharmaceutical products to address serious diseases.

Sarepta Therapeutics, Inc. (SRPT) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (B-); its weakest is Value (D-).

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
D-
Factor Score 1.0 / 5.0
Growth
D-
Factor Score 1.1 / 5.0
Profitability
B-
Factor Score 3.1 / 5.0
Momentum
B-
Factor Score 2.9 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 803.5
EV / EBITDA 81.0
Rev Growth YoY -4.5%
Gross Margin 23.4%
Price Return 3M -11.6%
Price Return 12M -10.7%
Catalyst Signal 0.00
Market Cap $1.7B
TTM Revenue $2.0B
Price / Sales 0.9
ROE -8.0%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 D- (1.0) D- (1.1) B- (3.1) B- (2.9) C+ (2.6) C- (2.1)
2026-11-08 D- (1.0) D- (1.1) B- (3.1) B- (3.0) C+ (2.6) C (2.2)
2026-11-01 B (3.3) D- (0.9) B- (3.0) C+ (2.8) C+ (2.7) C+ (2.5)
2026-10-25 B (3.3) D- (0.9) B- (3.1) C+ (2.7) C+ (2.6) C+ (2.5)
2026-10-18 B (3.3) D- (0.9) B- (3.1) C+ (2.7) C+ (2.6) C+ (2.5)
Page 1 of 8
…